Total Payments
$411,234
2024 Payments
$120,173
Companies
29
Transactions
391
Medicare Patients
775
Medicare Billing
$185,600
Payment Breakdown by Category
Consulting$204,804 (49.8%)
Other$155,433 (37.8%)
Travel$38,231 (9.3%)
Food & Beverage$10,422 (2.5%)
Research$1,863 (0.5%)
Education$480.11 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $204,804 | 88 | 49.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $147,296 | 54 | 35.8% |
| Travel and Lodging | $38,231 | 93 | 9.3% |
| Food and Beverage | $10,422 | 133 | 2.5% |
| Honoraria | $8,138 | 8 | 2.0% |
| Unspecified | $1,863 | 4 | 0.5% |
| Education | $480.11 | 11 | 0.1% |
Payments by Type
General
$409,371
387 transactions
Research
$1,863
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $90,037 | 89 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $68,202 | 55 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $48,823 | 35 | $0 (2023) |
| PFIZER INC. | $36,842 | 24 | $0 (2024) |
| Eli Lilly and Company | $33,819 | 6 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $22,725 | 22 | $0 (2024) |
| Mirati Therapeutics, Inc. | $22,409 | 17 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $22,133 | 20 | $0 (2024) |
| Daiichi Sankyo Inc. | $9,917 | 20 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $6,796 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $120,173 | 109 | Janssen Biotech, Inc. ($52,400) |
| 2023 | $95,107 | 95 | Mirati Therapeutics, Inc. ($22,409) |
| 2022 | $76,514 | 49 | Eli Lilly and Company ($29,469) |
| 2021 | $55,609 | 47 | Takeda Pharmaceuticals U.S.A., Inc. ($17,460) |
| 2020 | $28,530 | 27 | Takeda Pharmaceuticals U.S.A., Inc. ($7,286) |
| 2019 | $25,022 | 39 | AstraZeneca Pharmaceuticals LP ($22,163) |
| 2018 | $9,878 | 21 | AstraZeneca Pharmaceuticals LP ($8,518) |
| 2017 | $401.81 | 4 | Genentech USA, Inc. ($161.78) |
All Payment Transactions
391 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,275.00 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $495.88 | General |
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $443.43 | General |
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $52.45 | General |
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $5.35 | General |
| Category: Oncology | ||||||
| 12/13/2024 | PFIZER INC. | LORBRENA (Drug) | Travel and Lodging | In-kind items and services | $458.35 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | Cash or cash equivalent | $74.04 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | Cash or cash equivalent | $419.54 | General |
| Category: Oncology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 12/02/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,070.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | PFIZER INC. | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $5.61 | General |
| Category: ONCOLOGY | ||||||
| 11/24/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $154.94 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $708.02 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $264.09 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $130.10 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 11/20/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $126.79 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | Cash or cash equivalent | $72.20 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | Cash or cash equivalent | $56.00 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $5.20 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $589.56 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | Cash or cash equivalent | $215.70 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC | F. Hoffmann-La Roche AG | $749.32 | 1 |
| LCMC3 | F. Hoffmann-La Roche AG | $569.74 | 1 |
| LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC | F. Hoffmann-La Roche AG | $365.91 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $178.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 196 | 647 | $415,976 | $74,913 |
| 2022 | 5 | 190 | 437 | $271,199 | $52,268 |
| 2021 | 3 | 145 | 274 | $72,238 | $21,524 |
| 2020 | 5 | 244 | 524 | $127,546 | $36,896 |
Total Patients
775
Total Services
1,882
Medicare Billing
$185,600
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 92 | 500 | $316,500 | $57,796 | 18.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 47 | $37,055 | $6,390 | 17.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 29 | 29 | $23,113 | $4,106 | 17.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 24 | $21,168 | $3,229 | 15.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 27 | 32 | $13,760 | $2,618 | 19.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 11 | 15 | $4,380 | $774.62 | 17.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 60 | 197 | $124,701 | $24,421 | 19.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 23 | 59 | $47,141 | $9,379 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 37 | 100 | $43,000 | $8,184 | 19.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $23,113 | $3,963 | 17.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $16,558 | $3,120 | 18.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $9,702 | $1,865 | 19.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 24 | $6,984 | $1,335 | 19.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 42 | 105 | $28,122 | $8,337 | 29.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 18 | 52 | $12,406 | $4,404 | 35.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 22 | 22 | $14,165 | $3,725 | 26.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 39 | 60 | $10,992 | $3,018 | 27.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 24 | 35 | $6,553 | $2,040 | 31.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 73 | 232 | $52,027 | $14,995 | 28.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 32 | 97 | $21,856 | $5,771 | 26.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 28 | 28 | $15,101 | $4,777 | 31.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 28 | 28 | $13,125 | $3,916 | 29.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 48 | 85 | $12,870 | $3,556 | 27.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 22 | 35 | $9,687 | $3,068 | 31.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 13 | 19 | $2,880 | $814.81 | 28.3% |
About Dr. Misako Nagasaka, MD
Dr. Misako Nagasaka, MD is a Hematology & Oncology healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/18/2011. The National Provider Identifier (NPI) number assigned to this provider is 1063707958.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Misako Nagasaka, MD has received a total of $411,234 in payments from pharmaceutical and medical device companies, with $120,173 received in 2024. These payments were reported across 391 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($204,804).
As a Medicare-enrolled provider, Nagasaka has provided services to 775 Medicare beneficiaries, totaling 1,882 services with total Medicare billing of $185,600. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Orange, CA
- Active Since 06/18/2011
- Last Updated 03/21/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1063707958
Products in Payments
- RYBREVANT (Drug) $90,766
- LIBTAYO (Biological) $44,858
- EXKIVITY (Drug) $41,519
- TAGRISSO (Drug) $38,920
- LORBRENA (Drug) $33,719
- KRAZATI (Drug) $22,409
- IMFINZI (Drug) $11,285
- ENHERTU (Biological) $9,590
- Tecentriq (Biological) $5,390
- GILOTRIF (Drug) $5,180
- ALUNBRIG (Drug) $4,143
- Tepotinib $3,570
- TECENTRIQ (Biological) $3,425
- RETEVMO (Drug) $3,200
- GAVRETO (Drug) $3,075
- TABRECTA (Drug) $2,620
- Vitrakvi (Drug) $1,958
- IMFINZI (Biological) $1,882
- Non-Covered Product (Drug) $1,172
- MK-7339 (Drug) $633.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Orange
Dr. Arash Rezazadeh Kalebasty, M.d, M.D
Hematology & Oncology — Payments: $842,766
Hematology & Oncology $842,766
Dr. Catherine Coombs, M.d, M.D
Hematology & Oncology — Payments: $593,945
Hematology & Oncology $593,945
Sai-Hong I Ou, Md, MD
Hematology & Oncology — Payments: $489,003
Hematology & Oncology $489,003
John P Fruehauf, Md, MD
Hematology & Oncology — Payments: $185,304
Hematology & Oncology $185,304
Timothy Byun, Md, MD
Hematology & Oncology — Payments: $137,826
Hematology & Oncology $137,826
Sam Huang, M.d, M.D
Hematology & Oncology — Payments: $104,843
Hematology & Oncology $104,843